Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors.

Abstract

BACKGROUND:

The aim of the present study was to investigate the role of a multimodality treatment for anaplastic thyroid carcinoma (ATC).

METHODS:

Clinical data of 40 consecutive patients treated between 1985 and 2009 were retrospectively analyzed.

RESULTS:

The median survival time (MST) stratified by clinical stage was 6.0 months for stage IVB and 4.2 months for stage IVC. When the stage IVB patients were classified into 2 groups (IVB-a and IVB-b) in accord with the extent of involvement of the tumor, the MST of the patients with IVB-a (9.6 months) was significantly longer than that of patients with IVB-b (4.0 months) (p < .05). The MST of the patients treated with surgery followed by radiation and chemotherapy (13.7 months) tended to be longer compared with the patients treated with 2 or fewer modalities.

CONCLUSION:

The patients with a less-invasive primary tumor may gain a survival benefit from aggressive multimodality therapeutic approaches.

• Authors: Ken-Ichi Ito, Toru Hanamura, Koichi Murayama, Toshihiro Okada, Takayuki Watanabe, Michihiko Harada, Tokiko Ito, Hiroshi Koyama, Toshiharu Kanai, Kazuma Maeno, Yasuhiro Mochizuki, Jun Amano
• Journal: Head & neck (Head Neck) Vol. 34 Issue 2 Pg. 230-7 (Feb 2012) ISSN: 1097-0347 [Electronic] United States
• PMID: 21500309 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Wiley Periodicals, Inc.

Topics

• Aged
• Aged, 80 and over
• Combined Modality Therapy
• Female
• Humans
• Kaplan-Meier Estimate
• Lung Neoplasms (secondary)
• Male
• Middle Aged
• Neoplasm Invasiveness
• Neoplasm Staging
• Prognosis
• Retrospective Studies
• Thyroid Carcinoma, Anaplastic
• Thyroid Neoplasms (mortality, pathology, surgery, therapy)
• Thyroidectomy